Study of Immunomodulation Using Naltrexone and Ketamine for COVID-19

PHASE2

Phase

TERMINATED

Status

Enrollment

OTHER

Sponsor class

Stopped Because of the decrease in COVID cases, enrollment is extremely low. Given the current study design, it is not possible to gather data necessary to answer the question about whether study treatment reduces mortality

Conditions

COVID-19
Acute Respiratory Distress Syndrome
Severe Acute Respiratory Syndrome (SARS)
Coronavirus Infections

Interventions

DRUG: Naltrexone
DRUG: Ketamine
OTHER: Placebo

Sponsor

Corewell Health East